Table 4

 Effects of glyceryl trinitrate 1.25 mg/day through transdermal patch and rehabilitation versus rehabilitation alone in patients with supraspinatus tendinopathy (adapted from Paoloni et al20)

WeekActivePlacebop Value
Pain with activity—by shoulder
(n = 28)(n = 28)
22.22.10.80
61.92.10.34
121.61.90.36
241.01.80.006
Pain at rest—by shoulder
(n = 27)(n = 28)
21.71.90.47
61.51.60.68
121.11.40.19
240.71.20.09
Pain at night—by shoulder
(n = 27)(n = 27)
21.41.60.61
61.41.50.72
121.01.50.09
240.81.40.031
Tenderness—by shoulder
(n = 27)(n = 28)
20.10.40.012
60.20.50.017
120.20.40.18
240.20.20.60
Change from baseline in abduction range of motion—by shoulder
(n = 27)(n = 29)
27.71.50.15
67.82.00.29
1216.31.20.020
2426.68.70.004
Change from baseline in adduction power—by shoulder
(n = 27)(n = 28)
25.61.30.24
67.7−0.60.08
1211.90.40.023
249.91.60.11
Change from baseline in external rotation power—by shoulder
(n = 27)(n = 28)
24.70.50.17
67.40.80.11
1211.50.50.023
2413.40.30.013
Change from baseline in external rotation range of motion—by shoulder
(n = 27)(n = 27)
21.96.70.13
64.71.90.45
127.73.30.26
2413.28.50.17
Change from baseline in forward flexion—by shoulder
(n = 36)(n = 41)
27.80.80.11
66.5−2.30.09
1213.4−2.20.019
2420.36.30.027
Impingement external rotation (% with 0)—by shoulder
(n = 27)(n = 28)
240.732.10.51
640.732.10.57
1270.457.10.36
2470.450.00.15
Impingement internal rotation (% with 0)—by shoulder
(n = 27)(n = 28)
233.310.70.059
648.217.90.040
1251.932.10.15
2474.139.30.018
Change from baseline in internal rotation power—by shoulder
(n = 27)(n = 28)
24.9−0.90.14
610.82.00.055
1211.0−1.50.029
2413.91.10.018
Change from baseline in internal rotation range of motion—by shoulder
(n = 27)(n = 28)
2−2.30.50.37
6−4.3−1.00.22
12−5.00.60.15
24−8.1−0.30.32
Change from baseline in subscapularis power—by shoulder
(n = 27)(n = 28)
29.00.90.009
69.25.40.24
1214.05.80.045
2415.76.60.018
Change from baseline in supraspinatus power—by shoulder
(n = 27)(n = 28)
23.6−1.50.10
611.00.70.009
1215.42.00.010
2416.22.90.007